Singapore markets open in 7 hours 1 minute

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.7850+0.0550 (+2.03%)
As of 12:56PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.7300
Open2.8000
Bid2.7500 x 1000
Ask2.8100 x 3000
Day's range2.7101 - 2.7850
52-week range0.9630 - 3.7740
Volume21,777
Avg. volume91,020
Market cap202.532M
Beta (5Y monthly)3.14
PE ratio (TTM)N/A
EPS (TTM)-1.4100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.25
  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights01/31/202471,751,20177,686,818 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46

  • GlobeNewswire

    Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

    NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the second tranche of €15 million (“Tranche B”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the "Finance Contract"). Tranche B

  • GlobeNewswire

    Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

    NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommenda